Fatty Liver Is Reversible. The Scarring Is a Different Question.
Liver fat reverses faster than almost anything in metabolic medicine. The scarring does not. What FIB-4 shows, what GLP-1 medication changed, and why normal enzymes prove nothing.
A woman in her forties brought in a printout from her annual physical with one line circled: ALT 46. Her physician had told her it was mild, probably a bit of fatty liver, and that she should cut back on sugar. She felt completely well. No pain, no unusual fatigue, no yellowing of anything. She wanted to know whether a circled number on a page deserved a second thought.
It did. Not because 46 is alarming, but because the number was never the part that mattered.
What fatty liver actually is
Fat accumulating inside liver cells is not a disease of the liver alone. It is what metabolic dysfunction looks like when it shows up in an organ that does not complain.
The name changed in June 2023. What used to be called non-alcoholic fatty liver disease, or NAFLD, is now metabolic dysfunction-associated steatotic liver disease, MASLD. The inflamed form, previously NASH, is now MASH. The change was not cosmetic. The old name defined the condition by what it was not, alcohol, and said nothing about what it is. The new one names the cause.
To meet the definition you need fat in the liver on imaging or biopsy, plus at least one cardiometabolic criterion: a BMI of 25 or higher, or 23 in Asian populations, or an elevated waist circumference; fasting glucose of 100 mg/dL or more, HbA1c of 5.7% or more, or type 2 diabetes; blood pressure of 130/85 or higher, or treatment for it; triglycerides of 150 mg/dL or more; or HDL of 40 mg/dL or lower in men and 50 mg/dL or lower in women.
Read that list again. Every criterion is a metabolic one. This is insulin resistance expressed in liver tissue, the same process that runs quietly through the decade before anyone says the word diabetes.
Roughly 32.5% of American adults meet the definition. That is about one in three. A separate category, MetALD, covers people who have all of this and also drink meaningfully, above about 140 grams of alcohol a week for women and 210 for men, because in those cases two mechanisms are running at once and both need addressing.
Why it stays quiet
Early fatty liver produces no symptoms. Not mild symptoms. None.
The liver has no pain fibres in the tissue itself. The capsule around it can hurt when stretched, which is why significant swelling sometimes produces a dull ache under the right ribs, but that happens late and inconsistently. Most people with fat in the liver feel exactly as they did before. Some report fatigue, but fatigue is so common in people with insulin resistance, poor sleep and excess weight that attributing it to the liver specifically is usually guesswork.
So the honest answer to "what are the symptoms of fatty liver" is that for most people, for most of the time it is developing, there are none. That is precisely what makes it worth looking for rather than waiting for.
Two things follow from this, and both get missed.
A normal ALT does not rule out fatty liver. Plenty of people with significant steatosis, and some with established fibrosis, have liver enzymes sitting comfortably inside the reference range. Normal enzymes are reassuring about current inflammation, not about accumulated damage. It is the quiet cousin of being told your normal labs and still feeling unwell, except here the labs are normal and so, for now, is the feeling.
And a mildly raised ALT does not tell you how much fat is there or whether anything is scarred. It tells you some hepatocytes are leaking enzyme. The woman with the 46 could have had minimal disease or meaningful fibrosis. The number alone could not distinguish them.
How it is actually found, and what to ask for
If you have fat in the liver, the question that changes your life expectancy is not how much fat. It is how much scar tissue. The hormone underneath all of this moves early too, which is the argument in insulin moves before the scale does.
Fibrosis stage is the strongest predictor of liver-related outcomes. Fat on its own is common and, taken alone, relatively benign. Fibrosis is what progresses toward cirrhosis, and cirrhosis is what kills people.
The current pathway, updated by the American Gastroenterological Association in March 2026, works in two steps and starts with a calculation you can run from labs you have probably already had.
Step one, FIB-4. It uses age, AST, ALT and platelet count. Nothing extra is drawn. A score below 1.3, or below 2.0 if you are 65 or older, reliably excludes advanced fibrosis, with a negative predictive value above 90%. If you are below that line, you stay in routine care and repeat the calculation every one to two years.
Step two, liver stiffness. If FIB-4 is at or above the threshold, the next test is vibration-controlled transient elastography, usually called FibroScan. Below 8 kPa suggests low risk for clinically significant fibrosis. At 8 kPa or above, hepatology should be involved. Where elastography is not available, the enhanced liver fibrosis blood test can substitute, with a cutoff of 9.2.
Two practical notes. Abdominal ultrasound is the test most people get, and it has limited sensitivity for mild steatosis, so a clean ultrasound is weaker evidence than patients assume. And for people in high-risk groups, particularly anyone with type 2 diabetes, going straight to elastography rather than working through the two-step sequence is reasonable.
Biopsy still exists. It is no longer the routine route to a diagnosis. It is used when non-invasive testing is contradictory, when another liver disease is suspected alongside the metabolic one, or for clinical trial entry.
Who should be assessed at all: anyone with type 2 diabetes, anyone with overweight or obesity plus one more metabolic risk factor, and anyone with steatosis found incidentally on imaging or persistently raised aminotransferases.
What reverses, and what takes much longer
Here is the part that matters most, and it is the part the enthusiastic version of this topic skips.
Liver fat is genuinely reversible. It responds faster and more completely than almost anything else in metabolic medicine. Sustained weight loss in the range of 7% to 10% of body weight produces substantial reductions in hepatic fat, and the fat often begins falling well before that target is reached. This is real, repeatable, and the reason the question "can fatty liver be reversed" has an honest yes attached to it. What is being reversed is the same signalling failure described in why your cells stopped listening to insulin.
Fibrosis is a different tissue doing a different thing on a different timescale.
Scar tissue forms slowly in response to sustained injury, and it resolves slowly, incompletely, and not always. Early-stage fibrosis can regress when the driver is removed. Advanced fibrosis sometimes improves. Cirrhosis is generally considered the point at which the architecture of the organ has changed permanently, though even there, removing the cause changes the trajectory of complications.
Which produces a situation patients find genuinely confusing: liver fat can fall while scar tissue remains. Imaging improves. Enzymes normalise. The person feels, correctly, that something is better. And the fibrosis that determines their long-term risk has not moved yet, or has moved only slightly.
That is not a reason for pessimism. It is a reason to keep following the scarring separately from the fat, instead of assuming one number stands in for the other.
What GLP-1 medication changed
For most of the time I have practised, there was no approved drug for this. Treatment was weight loss, and the advice to lose weight is not a treatment plan. The same caution applies to the medications that followed, because a GLP-1 prescription is not a treatment plan either.
That changed. Resmetirom, a thyroid hormone receptor-beta agonist, was the first drug approved for MASH with F2 to F3 fibrosis, in 2024. Then in August 2025 the FDA granted accelerated approval to semaglutide 2.4 mg, marketed as Wegovy, for adults with non-cirrhotic MASH and moderate to advanced liver fibrosis. It is the first GLP-1 to carry a liver indication, and it is not indicated in cirrhosis.
The trial behind it, ESSENCE, reported results at 72 weeks. Steatohepatitis resolved without worsening fibrosis in 63% of treated patients compared with 34% on placebo. Fibrosis improved without worsening steatohepatitis in 37% versus 22%. Both outcomes together occurred in 33% versus 16%.
Note the placebo numbers. A third of the placebo group resolved their steatohepatitis. Everyone in that trial received lifestyle intervention, and a third of them got better on it. The medication roughly doubled the rate. It did not create a result that lifestyle cannot produce. The dose is a tool inside that plan rather than the plan itself, which is the same lesson as what to check before raising the dose.
Note also what accelerated approval means. It was granted on histology, the appearance of liver tissue, not on hard clinical outcomes such as progression to cirrhosis, liver failure or death. Whether the histological improvement translates into fewer of those events is being studied in the trial's longer phase and is not yet settled. I would call that likely rather than demonstrated.
Tirzepatide has produced similar-looking histological results in phase 2, with MASH resolution in roughly 62% of participants in SYNERGY-NASH. It is in phase 3 for this indication. It does not currently carry an FDA liver approval, and anyone telling you otherwise is ahead of the evidence.
Three things I would want you to leave with
You can be lean and have this. The cardiometabolic criteria include waist circumference and glucose and lipids, not only BMI. People with normal body weight and poor metabolic health develop fat in the liver, and they are frequently missed because nobody thinks to look. It is one piece of a larger arrangement, set out in the four hormonal systems that decide metabolic progress.
A falling scale is not proof of a recovered liver. Weight is a proxy. Liver fat and liver fibrosis are the actual measurements, and they are available. If you have been told you have fatty liver and nobody has calculated your FIB-4, that calculation costs nothing and uses labs you already have.
The silent phase is the useful phase. Everything in this article is more reversible earlier. The reason to act on a circled ALT when you feel completely well is that feeling well is not evidence of anything, and the window in which fat and early fibrosis respond is the window in which there is nothing to feel.
The woman with the 46 had a FIB-4 of 0.9. Her risk of advanced fibrosis was very low. We addressed the insulin resistance underneath it, and we will recalculate in a year. The circled number turned out to be the least informative thing on the page, and also the reason she asked the right question.
Sources: AASLD, New MASLD Nomenclature · FDA, Wegovy approval for MASH with liver fibrosis · AGA, updated MASLD care pathway (March 2026)
If any of this sounds like your experience, you can book a virtual consultation with Dr. Sater to review your history and testing in full.
This article is educational and is not individual medical advice. Speak with a qualified physician about your own health before making changes to your care.